Press releases

Company will make a special one-time contribution to its U.S. 401(k) Retirement Savings Plan and increase match amounts to six percent of pay.

Subsidiary Advanced Bionics Corporation is voluntarily recalling worldwide all unimplanted CLARION® and HiResolution® cochlear implants.

Together, studies presented will represent more than 10,000 patients.

Galway facility is one of two Company facilities that manufacture the TAXUS™ Express2™ paclitaxel-eluting coronary stent system.

Preliminary worldwide sales of TAXUS systems for the month of August were approximately $200 million.

Registry designed to assess physician usage patterns and evaluate outcome data in "real world" patients.

ATLAS clinical trial is the first trial using Boston Scientific's new Liberté™ coronary stent as a platform for its paclitaxel-eluting coronary stent system.

(August 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast a conference call providing updates on its business performance for 2004 and sales of its TAXUS™ Express2™...

(August 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its Peripheral Cutting...

(August 23, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its FilterWire EZ Embolic...